Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement
Journal of Psychopharmacology
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Rowlands, M.W.D.
Right arrow Articles by Cookson, J.C.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Rowlands, M.W.D.
Right arrow Articles by Cookson, J.C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

A double-blind placebo-controlled study of rolipram in depressed in-patients

M.W.D. Rowlands

Medical College of St Bartholomews Hospital

T. Silverstone

Medical College of St Bartholomews Hospital

J.C. Cookson

The London Hospital

In a double-blind study, rolipram, a new phosphodiesterase inhibitor, was com pared to placebo in 20 hospitalized depressed patients. There was a high rate of non- completion (11 out of 20) at 28 days. No difference was found in the clinical improvement between the two groups.

Journal of Psychopharmacology, Vol. 3, No. 3, 169-174 (1989)
DOI: 10.1177/026988118900300307
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




Advertisement